HistoSonics is pioneering a non-invasive, robotically assisted platform that utilizes focused sound energy to mechanically destroy diseased tissue at a sub-cellular level. The company operates in the medical technology sector, primarily serving healthcare providers and patients. HistoSonics' core technology, known as histotripsy, offers a non-ionizing and non-thermal treatment option, making it a safer alternative to traditional methods. The business model revolves around the development and commercialization of its proprietary platform, Edison™, which provides real-time treatment monitoring and procedural control. Revenue is generated through the sale of the Edison™ platform and associated services, including clinical trials and ongoing support. HistoSonics is currently conducting clinical trials in the United States and Europe under the HOPE4LIVER initiative, aiming to bring this innovative treatment to a broader market.

Keywords: histotripsy, non-invasive, robotically assisted, focused sound energy, sub-cellular, medical technology, Edison™, clinical trials, HOPE4LIVER, real-time monitoring.